These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1105 related items for PubMed ID: 32664888

  • 1. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H, Hayashi T, Takigami K, Imaizumi K, Shiroki R, Ohmiya N, Sugiura K, Kawada K, Sawaki A, Maeda K, Ando Y, Uyama I.
    BMC Cancer; 2020 Jul 14; 20(1):656. PubMed ID: 32664888
    [Abstract] [Full Text] [Related]

  • 2. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R.
    Eur J Cancer; 2019 Mar 14; 109():21-27. PubMed ID: 30682533
    [Abstract] [Full Text] [Related]

  • 3. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K, Nakamura T, Abe T, Ogusu S, Nakashima C, Takahashi K, Kimura S, Sueoka-Aragane N.
    Thorac Cancer; 2019 Sep 14; 10(9):1798-1804. PubMed ID: 31328416
    [Abstract] [Full Text] [Related]

  • 4. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L.
    Oncologist; 2019 Aug 14; 24(8):1128-1136. PubMed ID: 31015312
    [Abstract] [Full Text] [Related]

  • 5. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y.
    JAMA Oncol; 2019 Mar 01; 5(3):376-383. PubMed ID: 30589930
    [Abstract] [Full Text] [Related]

  • 6. Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Takada S, Hirokazu H, Yamagishi K, Hideki S, Masayuki E.
    Asian Pac J Cancer Prev; 2020 Jun 01; 21(6):1697-1699. PubMed ID: 32592366
    [Abstract] [Full Text] [Related]

  • 7. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
    Wang LX, Quach HT, Moodabigil NV, Davis EJ, Sosman JA, Dusetzina SB, Johnson DB.
    Cancer; 2020 Jan 15; 126(2):322-328. PubMed ID: 31580492
    [Abstract] [Full Text] [Related]

  • 8. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
    Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzutilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, Battelli N, Fargnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A.
    Eur J Cancer; 2020 Jul 15; 134():19-28. PubMed ID: 32454395
    [Abstract] [Full Text] [Related]

  • 9. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C.
    Oncologist; 2019 Jun 15; 24(6):e327-e337. PubMed ID: 30796151
    [Abstract] [Full Text] [Related]

  • 10. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V, Patwari A, Harb AJ.
    J Cancer Res Clin Oncol; 2021 Sep 15; 147(9):2789-2800. PubMed ID: 33774736
    [Abstract] [Full Text] [Related]

  • 11. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N.
    BMC Cancer; 2019 Oct 21; 19(1):974. PubMed ID: 31638948
    [Abstract] [Full Text] [Related]

  • 12. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.
    Clin Lung Cancer; 2019 Jul 21; 20(4):237-247.e1. PubMed ID: 30885550
    [Abstract] [Full Text] [Related]

  • 13. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
    Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A.
    Eur J Cancer; 2020 Apr 21; 129():71-79. PubMed ID: 32143106
    [Abstract] [Full Text] [Related]

  • 14. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA.
    Eur J Cancer; 2020 Mar 21; 128():17-26. PubMed ID: 32109847
    [Abstract] [Full Text] [Related]

  • 15. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N, Ithimakin S, Siripoon T, Sintawichai N, Sriuranpong V.
    BMC Cancer; 2021 Nov 25; 21(1):1275. PubMed ID: 34823493
    [Abstract] [Full Text] [Related]

  • 16. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors.
    Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Freyer G, Boespflug A, Péron J.
    Eur J Cancer; 2020 Jun 25; 132():61-70. PubMed ID: 32334337
    [Abstract] [Full Text] [Related]

  • 17. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N.
    Lung Cancer; 2018 Jan 25; 115():71-74. PubMed ID: 29290265
    [Abstract] [Full Text] [Related]

  • 18. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, Kwatra SG, Reynolds KL, Semenov YR.
    J Immunother Cancer; 2021 Mar 25; 9(3):. PubMed ID: 33789879
    [Abstract] [Full Text] [Related]

  • 19. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, Boucekine M, Mascaux C, Barlesi F.
    Clin Lung Cancer; 2019 May 25; 20(3):201-207. PubMed ID: 30442524
    [Abstract] [Full Text] [Related]

  • 20. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X.
    BMC Cancer; 2019 Jun 10; 19(1):558. PubMed ID: 31182061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.